KLRS
Kalaris Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Kalaris Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No changes.
No changes.
Annual filing, covered
10-K parsed · Mar 17 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 17 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
No thesis.
Largest filed tie
0
filed ties
—
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; no measured co-movers for Kalaris Therapeutics, Inc..
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; no measured co-movers for Kalaris Therapeutics, Inc..
Kalaris Therapeutics, Inc.
2.03
−0.02 · −0.98%
post 2.05 +0.99%
Expected move
No implied move.
| Manager | Value | % base | |
|---|---|---|---|
| Samsara BioCapital | $52.4M | 71.44% | −0.52% |
| RTW | $5.3M | 7.21% | 0.00% |
| Alyeska Investment | $2.3M | 3.18% | 0.00% |
| Siren | $1.8M | 2.42% | 0.00% |
| Vanguardindex-like | $1.6M | 2.21% | +56.14% |
| Manager | Value | % base | |
|---|---|---|---|
| Samsara BioCapital | $52.4M | 71.44% | −0.52% |
| RTW | $5.3M | 7.21% | 0.00% |
| Alyeska Investment | $2.3M | 3.18% | 0.00% |
| Siren | $1.8M | 2.42% | 0.00% |
| Vanguardindex-like | $1.6M | 2.21% | +56.14% |